PPAR agonists in health and disease: a pathophysiologic and clinical overview
- 1 August 2002
- journal article
- Published by Wolters Kluwer Health in Current Opinion in Endocrinology, Diabetes and Obesity
- Vol. 9 (4) , 285-302
- https://doi.org/10.1097/00060793-200208000-00002
Abstract
No abstract availableThis publication has 99 references indexed in Scilit:
- Expression and Function of Peroxisome Proliferator–Activated Receptor-γ in Mesangial CellsHypertension, 2001
- Control of Vascular Cell Proliferation and Migration by PPAR-γDiabetes Care, 2001
- Activation of Human Peroxisome Proliferator-Activated Receptor (PPAR) Subtypes by PioglitazoneBiochemical and Biophysical Research Communications, 2000
- Fenofibrate and Rosiglitazone Lower Serum Triglycerides with Opposing Effects on Body WeightBiochemical and Biophysical Research Communications, 2000
- Regulation of Gene Expression by Activation of the Peroxisome Proliferator-Activated Receptor γ with Rosiglitazone (BRL 49653) in Human AdipocytesBiochemical and Biophysical Research Communications, 1999
- Thiazolidinediones Down-Regulate Plasminogen Activator Inhibitor Type 1 Expression in Human Vascular Endothelial Cells: A Possible Role for PPARγ in Endothelial FunctionBiochemical and Biophysical Research Communications, 1999
- Obesity Associated with a Mutation in a Genetic Regulator of Adipocyte DifferentiationNew England Journal of Medicine, 1998
- Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factorCell, 1994
- Relation of carotid artery wall thickness to diabetes mellitus, fasting glucose and insulin, body size, and physical activity. Atherosclerosis Risk in Communities (ARIC) Study Investigators.Stroke, 1994
- Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with DyslipidemiaNew England Journal of Medicine, 1987